Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
04 mai 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
13 avr. 2021 16h01 HE
|
Nurix Therapeutics, Inc.
On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Strong financial position after...
Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
07 avr. 2021 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....
Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
05 avr. 2021 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers
16 mars 2021 09h31 HE
|
Nurix Therapeutics, Inc.
Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastomaProgram is one of four in Alex’s Lemonade Stand Foundation-funded $18.5 million Crazy 8...
4 Report Package: "Drug the Undruggable" Technologies Bundle - Four Full Reports for the Price of Two
12 mars 2021 04h13 HE
|
Research and Markets
Dublin, March 12, 2021 (GLOBE NEWSWIRE) -- The "Report Package: "Drug the Undruggable" Technologies" report has been added to ResearchAndMarkets.com's offering. This report package includes four...
Arvinas to Participate in Upcoming Virtual Investor Conferences
10 mars 2021 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences
09 mars 2021 07h30 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur...
Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock
02 mars 2021 16h15 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has...
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
01 mars 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,...